Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Gains from Sales and Divestitures (2016 - 2018)

International Stem Cell (ISCO) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $9855.0 as the latest value for Q4 2018.

  • On a quarterly basis, Gains from Sales and Divestitures fell 67.84% to $9855.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $9855.0, a 67.84% decrease, with the full-year FY2018 number at $9855.0, down 67.84% from a year prior.
  • Gains from Sales and Divestitures was $9855.0 for Q4 2018 at International Stem Cell, roughly flat from $9855.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $299838.0 in Q1 2015 to a low of $5527.0 in Q1 2018.
  • A 5-year average of $34605.5 and a median of $13926.0 in 2017 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 99.29% in 2014, then skyrocketed 183.61% in 2016.
  • International Stem Cell's Gains from Sales and Divestitures stood at $7309.0 in 2014, then skyrocketed by 180.68% to $20515.0 in 2015, then soared by 183.61% to $58182.0 in 2016, then tumbled by 47.33% to $30643.0 in 2017, then crashed by 67.84% to $9855.0 in 2018.
  • Per Business Quant, the three most recent readings for ISCO's Gains from Sales and Divestitures are $9855.0 (Q4 2018), $9855.0 (Q3 2018), and $9855.0 (Q2 2018).